Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform Eli Lilly's Mounjaro. Regulatory approval for Wegovy's cardiovascular benefits has been granted, pending final approval, allowing cardiologists to prescribe it.